Enanta Pharmaceuticals' Q4 Results Pulled Down by AbbVie's Sinking HCV Sales
Enanta Pharmaceuticals' (NASDAQ: ENTA) got off to a great start in 2019 with its shares soaring more than 40%. It's been downhill since the first quarter, though. The pharma stock is now down more than 10% year to date.
Any hopes that Enanta's fiscal 2019 fourth-quarter results would help turn things around were dashed on Thursday when the company provided its Q4 update after the market closed. Here are the highlights from the drugmaker's latest quarterly results.
Image Source: Getty Images.
Source Fool.com
